Table 2.

PSA-Progression Definitions

PSA-Progression Definition*	Trial
	S9346 (HSPC)				S9916 (CRPC)
	Events		PSA PFS (months)†		Events		PSA PFS (months)†
	No.	%	Median	95% CI	No.	%	Median	95% CI
Rising trend increase	669	62	14.5	12.3 to 16.6	458	77	5.7	5.0 to 6.2
50% + 5‡	435	40	64.1	NA§	346	58	11.7	10.8 to 12.6
25% + 5‡	440	41	61.5	NA§	396	66	9.5	8.4 to 10.5
PSAWG 1999 (25% + 5; or, if PSA declined by ≥ 50%, 50% + 5)‡	435	40	64.1	NA§	380	64	10.2	9.2 to 11.3
PCWG 2008 (25% + 2)‡	528	49	36.1	30.5 to 44.2	415	70	8.1	7.0 to 9.5

Abbreviations: PSA, prostate-specific antigen; PFS, progression-free survival; HSPC, hormone-sensitive prostate cancer; CRPC, castration-resistant prostate cancer; PSAWG, Prostate-Specific Antigen Working Group; PCWG, Prostate Cancer Working Group.

^*All definitions are based on increases above the prostate-specific antigen nadir.

^†Kaplan-Meier estimates, in months.

^‡50% + 5 indicates an increase of prostate-specific antigen by ≥ 50% and an absolute increase of ≥ 5 ng/mL; 25% + 5 indicates an increase by ≥ 25% and ≥ 5 ng/mL; 25% + 2 indicates an increase by ≥ 25% and ≥ 2 ng/mL.

^§95% confidence intervals not estimable when too few prostate-specific antigen progression events were observed.